Header - Quiénes Somos


TOWA PHARMACEUTICAL CO., LTD. Is Already the new owner of Pensa Pharma S.A / SPA/ AB / Gmbh /  toLife S.A.


The operation for which Towa has acquired the generics business from Esteve generics materialized on January 30, 2020 and culminated in a visit by Mr. Yoshida, president of Towa, to the manufacturing plant in Martorelles, where he personally greeted all the employees one by one.


Barcelona.  3rd February of 2020. TOWA PHARMACEUTICAL CO.,LTD. (Osaka, Japón) (TOWA) has completed the acquisition of 100% of the generic´s business of the Spanish pharmaceutical company Esteve,  as we advanced last December.

With the acquisition of Pensa, Towa will be able to supplu supply high quality and value-added generic medicines to patients not only in Japan but also in the rest of the world , through Pensa’s Spanish manufacturing plant specialized in pellets and its network of subsidiaries in Europe and the US.


Towa Pharmaceutical highly values current organization and culture and intends to maintain all the current management to drive further growth of the business in the future. No significant changes are expected to occur after the transaction.

Itsuro Yoshida, president of TowA Pharmaceutical, also visited Martorelles manufacturing plant and addressed employees in Spanish, Catalan and English to welcome them to Towa pharmaceutical and to convey to them the satisfaction that this purchase represents for their Project to create a large global company leader in generic and has all Pensa people. After the welcome, Mr. Yoshida greeted everyone present one by one



TOWA PHARMACEUTICAL CO., LTD. (, a company specializing in generic drugs and based in Kadoma, Osaka (Japan), has been dedicated to the research and development, production, and marketing of generic drugs since 1951. With a team of more than 3,100 employees, its annual sales total 105,104 million yen (as of March 2019). TOWA’s shares are listed on the Tokyo Stock Exchange (TSE).

Our finished product manufacturing plant is located 20km from Barcelona (Spain), where we simultaneously carry out our own as well as third party manufacturing. Within an area of over 30,000 m2, our state-of-the-art facilities currently manufacture over 120 million units a year corresponding to more than 600 pharmaceutical references.